Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

6 Feb 2008 07:01

Angle PLC06 February 2008 For Immediate Release 6 February 2008 ANGLE plc ('ANGLE' or the 'Company') ANGLE selected for Long-term Management Contract with London Development Agency Knowledge Connect Programme ANGLE plc (AIM:AGL), the intellectual property and technology commercialisationcompany, announces that it has been selected as a preferred bidder for a majornew management contract worth £3.7 million over the next three years. ANGLE has been selected by the London Development Agency (LDA), subject tocontract, for the delivery of the Knowledge Connect Programme. The KnowledgeConnect Programme aims to increase the level of business research anddevelopment in London by creating new collaborations between business and theLondon knowledge base, with a focus on enterprises that have not previouslyworked with this sector. This flagship Programme, a core part of the LDA's Knowledge Transfer Strategy,will engage with 1,600 businesses and involve ANGLE working intensively with 265businesses across London. The Programme is being established to raise theperformance and aspirations of London's businesses by providing effectivesupport for research and development, knowledge transfer and innovation acrossthe Capital. ANGLE was selected following a competitive tendering process on the basis of itsexperience in delivering similar business support programmes in London, UK wideand internationally. Additionally ANGLE has developed techniques which, it wasable to demonstrate, have secured successful knowledge transfer from academicand research institutions and have measurable business benefits for a wide rangeof small and medium sized enterprises (SMEs). Andrew Newland, Chief Executive of ANGLE, said: "This represents a major success for our Management services business andunderlines our strategy of focusing on long-term and profitable contracts. Inaddition to generating new revenue for ANGLE it also clearly illustrates theattraction of our business model for SMEs looking to develop and commercialisetheir IP. "We are delighted to have been selected to partner the London Development Agencyin this new project. Our team is looking forward to working with London'sbusinesses to help identify new opportunities and secure business growth throughknowledge transfer and innovation." Garth Selvey, Chairman of ANGLE, added: "This project adds to the strength of our Management services business, whichprovides the platform for ANGLE's ongoing operation. As stated in our InterimResults for the six months ended 31 October 2007 released on 31 January 2008,the Board believes that several of ANGLE's portfolio companies have thepotential to deliver substantial cash returns for shareholders." Enquiries:ANGLE plc +44 (0)1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.